» Articles » PMID: 38526491

Sarcopenia and Sarcopenic Obesity and Mortality Among Older People

Abstract

Importance: Sarcopenia and obesity are 2 global concerns associated with adverse health outcomes in older people. Evidence on the population-based prevalence of the combination of sarcopenia with obesity (sarcopenic obesity [SO]) and its association with mortality are still limited.

Objective: To investigate the prevalence of sarcopenia and SO and their association with all-cause mortality.

Design, Setting, And Participants: This large-scale, population-based cohort study assessed participants from the Rotterdam Study from March 1, 2009, to June 1, 2014. Associations of sarcopenia and SO with all-cause mortality were studied using Kaplan-Meier curves, Cox proportional hazards regression, and accelerated failure time models fitted for sex, age, and body mass index (BMI). Data analysis was performed from January 1 to April 1, 2023.

Exposures: The prevalence of sarcopenia and SO, measured based on handgrip strength and body composition (BC) (dual-energy x-ray absorptiometry) as recommended by current consensus criteria, with probable sarcopenia defined as having low handgrip strength and confirmed sarcopenia and SO defined as altered BC (high fat percentage and/or low appendicular skeletal muscle index) in addition to low handgrip strength.

Main Outcome And Measure: The primary outcome was all-cause mortality, collected using linked mortality data from general practitioners and the central municipal records, until October 2022.

Results: In the total population of 5888 participants (mean [SD] age, 69.5 [9.1] years; mean [SD] BMI, 27.5 [4.3]; 3343 [56.8%] female), 653 (11.1%; 95% CI, 10.3%-11.9%) had probable sarcopenia and 127 (2.2%; 95% CI, 1.8%-2.6%) had confirmed sarcopenia. Sarcopenic obesity with 1 altered component of BC was present in 295 participants (5.0%; 95% CI, 4.4%-5.6%) and with 2 altered components in 44 participants (0.8%; 95% CI, 0.6%-1.0%). An increased risk of all-cause mortality was observed in participants with probable sarcopenia (hazard ratio [HR], 1.29; 95% CI, 1.14-1.47) and confirmed sarcopenia (HR, 1.93; 95% CI, 1.53-2.43). Participants with SO plus 1 altered component of BC (HR, 1.94; 95% CI, 1.60-2.33]) or 2 altered components of BC (HR, 2.84; 95% CI, 1.97-4.11) had a higher risk of mortality than those without SO. Similar results for SO were obtained for participants with a BMI of 27 or greater.

Conclusions And Relevance: In this study, sarcopenia and SO were found to be prevalent phenotypes in older people and were associated with all-cause mortality. Additional alterations of BC amplified this risk independently of age, sex, and BMI. The use of low muscle strength as a first step of both diagnoses may allow for early identification of individuals at risk for premature mortality.

Citing Articles

Training modalities for elder sarcopenic obesity: a systematic review and network meta-analysis.

Qiu H, Zheng W, Zhou X, Liu Q, Zhao X Front Nutr. 2025; 12:1537291.

PMID: 40046765 PMC: 11879820. DOI: 10.3389/fnut.2025.1537291.


Prevalence of Sarcopenia Among Slovenian Older Adults and Associated Risk Factors.

Pus K, Pisot S, Marusic U, Peskar M, Teraz K, Kalc M Zdr Varst. 2025; 64(2):103-111.

PMID: 40026371 PMC: 11870320. DOI: 10.2478/sjph-2025-0013.


Development and multi-center cross-setting validation of an explainable prediction model for sarcopenic obesity: a machine learning approach based on readily available clinical features.

Lian R, Tang H, Chen Z, Chen X, Luo S, Jiang W Aging Clin Exp Res. 2025; 37(1):63.

PMID: 40021576 PMC: 11870957. DOI: 10.1007/s40520-025-02975-z.


The combined impact of BMI and ABSI on all-cause mortality among American adults with diabetes.

Wei S, Jiang W, Zheng H, Zhang J, Yang J, Wang Y Diabetol Metab Syndr. 2025; 17(1):48.

PMID: 39920852 PMC: 11806875. DOI: 10.1186/s13098-025-01614-x.


Sheer drop ahead: reviewing sarcopenia outcomes in elderly patients undergoing bariatric surgery.

Stumpf M, Cercato C, de Melo M, Mancini M Rev Endocr Metab Disord. 2025; .

PMID: 39920515 DOI: 10.1007/s11154-025-09946-9.


References
1.
Cruz-Jentoft A, Gonzalez M, Prado C . Sarcopenia ≠ low muscle mass. Eur Geriatr Med. 2023; 14(2):225-228. DOI: 10.1007/s41999-023-00760-7. View

2.
Donini L, Busetto L, Bischoff S, Cederholm T, Ballesteros-Pomar M, Batsis J . Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement. Obes Facts. 2022; 15(3):321-335. PMC: 9210010. DOI: 10.1159/000521241. View

3.
Zhang X, Wang C, Dou Q, Zhang W, Yang Y, Xie X . Sarcopenia as a predictor of all-cause mortality among older nursing home residents: a systematic review and meta-analysis. BMJ Open. 2018; 8(11):e021252. PMC: 6252774. DOI: 10.1136/bmjopen-2017-021252. View

4.
Matsushita T, Nishioka S, Taguchi S, Yamanouchi A, Nakashima R, Wakabayashi H . Sarcopenic Obesity and Activities of Daily Living in Stroke Rehabilitation Patients: A Cross-Sectional Study. Healthcare (Basel). 2020; 8(3). PMC: 7551564. DOI: 10.3390/healthcare8030255. View

5.
Vieira F, Godziuk K, Lamarca F, Melendez-Araujo M, Lima R, Prado C . Sarcopenic obesity diagnosis by different criteria mid-to long-term post-bariatric surgery. Clin Nutr. 2022; 41(9):1932-1941. DOI: 10.1016/j.clnu.2022.07.006. View